A new real-world analysis of patients with chronic lymphocytic leukemia (CLL) and small cell lymphocytic leukemia (SLL) indicates that the risk of adverse events is lower...
Final results of the EVIdeNCE study strongly support ibrutinib (Imbruvica; AbbVie/Pharmacyclics) as a valuable treatment option for patients with chronic lymphocytic leukemia (CLL). The EVIdeNCE data,...